Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150035/S042

AVEIR VR Real-World Evidence Study

ABBOTT MEDICAL · Decision date Oct 21, 2026

MEDTECHLEDGER EXPLANATIONP150035/S042

What did the FDA approve?

The FDA record shows an approval dated 2026-10-21 for a revised protocol governing the post-approval study (PAS) tied to P150035/S042. The supplement is filed under the Normal 180 Day Track No User Fee pathway, with the stated reason "Postapproval Study Protocol." The changed item is the PAS protocol itself, not the underlying PMA for the leadless pacemaker (product code PNJ, cardiovascular specialty, applicant Abbott Medical).

The supplied statement says the protocol was submitted to comply with conditions of approval in the earlier approval order for P150035/S041, which is the only stated link to the original PMA. That describes a filing purpose, not independent evidence of safety or clinical effectiveness. Details absent from the source include study endpoints, sample size, follow-up duration and the specific conditions being addressed, so the protocol's substantive requirements cannot be described here.

FDA approval order statement

approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P150035/S041.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Oct 21, 2026
FDA change category
Postapproval Study Protocol

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150035/S042
Regulatory pathway
PMA supplement
Product code
PNJ
Decision code
APPR
Decision date
Oct 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Leadless pacemaker.

Product code
PNJ
FDA device class
3

For the original device and its historical approval scope, see PMA P150035. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150035 · Original PMA

    Aveir VR Leadless System

  2. P150035/S042 received

    Application receipt date recorded by FDA.

  3. P150035/S042 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P150035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150035

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalMar 31, 2022FDA

Explore the linked device profile

Other records with product code PNJ

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementSep 8, 2026FDA
Medtronic, Inc.PMA approvalApr 6, 2016FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
15900 Valley View Ct., Sylmar, CA, 91342

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records